Targanta Therapeutics Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Employees
-
113
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$132M
- Investors
-
1
Targanta Therapeutics General Information
Description
Developer of innovative antibiotics to treat serious infections in the hospital and other institutional settings. The company develops antibiotics for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections.
Contact Information
Corporate Office
- 222 Third Street
- Suite 2300
- Cambridge, MA 02142
- United States
Corporate Office
- 222 Third Street
- Suite 2300
- Cambridge, MA 02142
- United States
Targanta Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 26-Feb-2009 | $132M | Completed | Clinical Trials - Phase 3 | ||
| 6. IPO | 10-Oct-2007 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC (Series C3) | 12-Feb-2007 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C2) | 06-Jan-2005 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C1) | 12-Mar-2002 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 01-Dec-1999 | $28.7M | $30.3M | Completed | Product Development | |
| 1. Seed Round | 01-Dec-1997 | $1.58M | $1.58M | Completed | Startup |
Targanta Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C3 | ||||||||
| Series C2 | ||||||||
| Series C1 | ||||||||
| Series B | 245,000 | $0.000100 | 8% | $199.5 | $199.5 | 1x | $199.5 | 1.35% |
| Series A | 20,000 | $0.000100 | $101.12 | $101.12 | 1x | $101.12 | 0.15% |
Targanta Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Targanta Therapeutics Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brookside Capital | Venture Capital | Minority | ||
| Fonds de solidarite FTQ | PE/Buyout | Minority | ||
| GrowthWorks | Venture Capital | Minority | ||
| InterMune | Corporation | |||
| Le Centre CDP Capital | Venture Capital | Minority |
Targanta Therapeutics FAQs
-
When was Targanta Therapeutics founded?
Targanta Therapeutics was founded in 1997.
-
Where is Targanta Therapeutics headquartered?
Targanta Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Targanta Therapeutics?
Targanta Therapeutics has 113 total employees.
-
What industry is Targanta Therapeutics in?
Targanta Therapeutics’s primary industry is Pharmaceuticals.
-
Is Targanta Therapeutics a private or public company?
Targanta Therapeutics is a Private company.
-
What is the current valuation of Targanta Therapeutics?
The current valuation of Targanta Therapeutics is .
-
What is Targanta Therapeutics’s current revenue?
The current revenue for Targanta Therapeutics is .
-
How much funding has Targanta Therapeutics raised over time?
Targanta Therapeutics has raised $193M.
-
Who are Targanta Therapeutics’s investors?
Brookside Capital, Fonds de solidarite FTQ, GrowthWorks, InterMune, and Le Centre CDP Capital are 5 of 12 investors who have invested in Targanta Therapeutics.
-
When was Targanta Therapeutics acquired?
Targanta Therapeutics was acquired on 26-Feb-2009.
-
Who acquired Targanta Therapeutics?
Targanta Therapeutics was acquired by The Medicines Company.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
